PIPELINE

INDICATION
PHASE 1
PHASE 2
PHASE 3
UPCOMING MILESTONES
Pancreatic Cancer (Fast track designation)
Elraglusib (Elra) + gem/Abraxane (1st line, randomized)
PHASE 1
PHASE 2
PHASE 3
Study 1801 (enrolling)
Topline Data – 3Q23
Pancreatic Cancer (Fast track designation)
Elra + FOLFIRINOX + Losartan (1st line, randomized)
PHASE 1
PHASE 2
PHASE 3
Study 2103
Initial data – 1H23
Pancreatic Cancer (Fast track designation)
Elra + Anti-PD-1 + gem/Abraxane (1st line, single arm)
PHASE 1
PHASE 2
PHASE 3
Study 2105
Initial data – 1H23
Metastatic Melanoma
Elra+carbo/paclitaxel
ICI failures (3rd line+)
PHASE 1
PHASE 2
PHASE 3
Study 1801 Extension
Initiation – 2H22
Elra+carbo/paclitaxel RCT
Advanced ovarian, lung, or esophageal
PHASE 1
PHASE 2
PHASE 3
Study 1801 Extension
Initiation – 2H22
Adult T-Cell Leukemia/Lymphoma
Elraglusib (single arm)
PHASE 1
PHASE 2
PHASE 3
Study 1801 Extension
Initiation – 2H22
Salivary Gland Carcinoma
Elra + Carboplatin (single arm)
PHASE 1
PHASE 2
PHASE 3
Study 2102 (enrolling)
Initial Data - 1H23
Myelofibrosis (Active, Not Recruiting)
Elra +Ruxolitinib, single arm
PHASE 1
PHASE 2
PHASE 3
Study 1901
IV Cohort Data – 2H22
Pediatric (refractory)
(Rare Pediatric Disease Designation & Waiver)
Elra +chemotherapy (single arm)
Phase 2 pending oral
PHASE 1
PHASE 2
PHASE 3
Study 1902 (enrolling)
Phase 1 Data – 1H23